The final Question and Answer are interesting!...and exciting!
CD: My final question is on collaboration. I realized that, as Paul said, you can start and possibly finish this trial with the capital resources you have. But it seems to me that there is potential for collaboration whose interest might have increased since all the immunotherapy focus in ASCO. Has there been an increase in bavituximab since then? And what is the feedback? And then finally, is Cotara still on the table as a potential source of collaboration?
SK: Yes, Cotara's essentially on the table as a good collaborative discussion point with potential partners so that certainly, there is another source of partnering activity. I would characterize it as a tremendous amount of interest with the new immunotherapy mechanism data. I think there's a lot of collaboration interest with companies that are actually very active in the immunotherapy space because of the nature of our upstream target, the fact that we're going after really a primary endpoint of control in the immune response to the tumor, it really creates a lot of opportunities with these downstream effectors, and of course, PD-1, PDL-1 and CTLA-4 were certainly hot topics at ASCO. But there are a lot of other opportunities with downstream inhibitors that we think are a great fit with bavituximab. So, yes, I think it just opens up a whole new world of collaboration opportunities well outside just the kind of where we've been historically with chemotherapy and other types of treatment, like radiation, and really opening up a whole bunch of new doors that are really a very intense area of research right now.
Market Data 
Markets 
AI
